Local pharmaceutical firm Glovax Biotech Corp. yesterday said it has the support of big businesses, MVP and SM Groups in its bid to facilitate the country’s vaccination rollout against the new coronavirus disease 2019 (COVID-19).
Giovanni Alingog, Glovax chief executive officer, said in a statement the company and its joint venture partner Eubilogics of Korea will submit this April to government an application for the clinical trial of the EuCorVac-19 COVID vaccine to be manufactured in Korea and eventually in the Philippines.
Alingog said Glovax is in talks with the MVP Group for possible collaboration with PayMaya, Smart Communication, Manila Electric Co. as well as the MPIC Hospitals Group.
He did not provide details but said Glovax also intends to supply the vaccine to these private companies.
According to Alingog, Glovax will make available the EuCorVac-19 in all its Vaxcen Bakuna Centers to be located in all 76 SM Malls nationwide starting with Megamall, The Block North Edsa, MOA and Clark.
The Vaxcen Bakuna Center caters to all available vaccines such as influenza, pneumonia and rabies vaccines all year round.
Glovax earlier announced it will be putting up a P7-billion manufacturing plant for EuCorVac-19 with EuBiologics as technical partner.
The EuCorVac-19 clinical trial will be first of its kind in the Philippines using platform-to-platform comparison with other manufacturers for efficacy, immunogenicity and safety.
Glovax is in talks with the Department of Health and the Department of Science and Technology for the inclusion of EuCorVac-19 in local clinical trials and the Resbakuna Program.
Alingog said Glovax was earlier endorsed by Secretary Carlito Galvez Jr., chief implementer and vaccine czar of the National Task Force Against COVID-19 to the DOST for a possible tripartite agreement.
Alingog said EuCorVac-19 was y approved for Phase 1 and Phase 2 clinical trials in Korea.
Glovax earlier said it will apply for the emergency use authorization of the vaccie.